Place Raymond Blyckaerts, 13
B-1050 Brussels, Belgium

Opening hours:
Mon to Thu: 10h - 12h30 and 13h30 - 17h
Fri: 10h - 12h30 and 13h30 - 16h


+3226269640
Google maps


Find us on
Google Maps
To subscribe to our newsletter, please click here. If you would like to become an EATG member, please fill in the form here. You can also subscribe to our RSS feed by clicking here.
You can also follow us on one of these media :
TAGS

24/10/2014
Hepatitis C and drug use manifesto online - sign now!

On October 23, 2014 during the Hepatitis C and Drug Use Conference in Berlin, a declaration was launched with 7 points for a better Hepatitis policy in Europe and abroad. The declaration is initially signed by the Correlation Network, Harm Reduction International (HRI), the International Network of People Who Use Drugs (INPUD) and the European Association of the Study of the Liver (EASL)....

Read more...





24/10/2014
A new dent in HIV-1's armor

Salk scientists identify a promising target for HIV/AIDS treatment LA JOLLA–Like a slumbering dragon, HIV can lay dormant in a person’s cells for years, evading medical treatments only to wake up and strike at a later time, quickly replicating itself and destroying the immune system. Scientists at the Salk Institute have uncovered a new protein that participates...

Read more...

Source Source: Salk Institute





24/10/2014
PIs and raltegravir favored over NNRTIs for frail and older people

Protease inhibitors (PIs) and the integrase inhibitor raltegravir got prescribed significantly more often for people in the oldest and frailest quartiles of an Italian HIV cohort [1]. Clinicians used nonnucleosides (NNRTIs) most often for the youngest and least frail patients.   Guidelines offer advice on antiretroviral options in patients with viral rebound, poor CD4 gains, or...

Read more...

Source Source: NATAP





24/10/2014
Switch from PI or NNRTI to Stribild in people 50 or older effective and safe in trials

Switching from a ritonavir-boosted protease inhibitor (PI) or a nonnucleoside (NNRTI) to single-tablet Stribild (elvitegravir/cobicistat/tenofovir/emtricitabine) proved effective and safe in people 50 or older enrolled in the STRATEGY-PI and STRATEGY-NNRTI trials [1]. Patient satisfaction scores were higher in people who switched to Stribild than in those who maintained their PI or NNRTI...

Read more...

Source Source: NATAP





24/10/2014
Kidney disease key cofactor in coronary artery disease risk with HIV at 60 and older

HIV infection almost tripled chances of coronary artery disease (CAD) in a comparison of 1253 Delaware residents at least 60 years old with and without HIV--but only among people who had chronic kidney disease (CKD) [1]. Women with CKD had a 70% lower chance of CAD than men.   Clinical researchers at the Christiana Care Health System in Wilmington noted that noninfectious...

Read more...

Source Source: NATAP